

Supplemental Table 5. Unadjusted analyses of associations between demographic and clinical characteristics and COVID-19 hospitalization

Variable	No COVID-19 Hospitalization N = 5,769,906	COVID-19 Hospitalization N = 36,321	Unadjusted analysis	
	N (%) or Mean (SD)	N (%) or Mean (SD)	Hazard Ratio (95% CI)	p-value
Non-infectious uveitis	29,506 (0.5)	363 (1.0)	1.91 (1.72, 2.12)	<0.001
Age (years)	50.1 (23.5)	72.2 (13.7)	1.060 (1.059, 1.061)	<0.001
Gender			Reference	
Female	2,968,625 (51.5)	18,153 (50.0)		
Male	2,798,250 (48.5)	18,156 (50.0)	1.07 (1.05, 1.09)	<0.001
Unknown	3,031 (0.05)	12 (0.03)	0.60 (0.34, 1.06)	0.08
Race/ethnicity			Reference	
White	3,716,891 (64.4)	20,805 (57.3)		
Asian	299,098 (5.2)	963 (2.7)	0.60 (0.56, 0.64)	<0.001
Black	580,077 (10.1)	7,220 (19.9)	2.24 (2.18, 2.30)	<0.001
Hispanic	670,909 (11.6)	5,337 (14.7)	1.47 (1.42, 1.51)	<0.001
Other/Unknown	502,931 (8.7)	1,996 (5.5)	0.69 (0.66, 0.72)	<0.001
Region			Reference	
South	2,485,688 (43.1)	17,818 (49.1)		
Midwest	1,525,091 (26.4)	10,141 (27.9)	0.92 (0.90, 0.94)	<0.001
Northeast	634,747 (11.0)	5,629 (15.5)	1.23 (1.20, 1.27)	<0.001
West	945,467 (16.4)	2,686 (7.4)	0.41 (0.40, 0.43)	<0.001
Other/Unknown	178,913 (3.1)	47 (0.1)	0.04 (0.03, 0.05)	<0.001
Homeownership			Reference	
Probable homeowner	3,956,854 (68.6)	24,507 (67.5)		
Probable renter	440,102 (7.6)	2,766 (7.6)	1.06 (1.02, 1.10)	0.006
Unknown	1,372,950 (23.8)	9,048 (24.9)	1.10 (1.07, 1.13)	<0.001
Smoking status			Reference	
Never smoker	845,134 (14.7)	5,929 (16.3)		
Current/former smoker	925,365 (16.0)	13,112 (36.1)	2.05 (1.98, 2.11)	<0.001
Unknown	3,999,407 (69.3)	17,280 (47.6)	0.64 (0.62, 0.66)	<0.001
Asthma	32,4058 (5.6)	3,562 (9.8)	1.81 (1.75, 1.87)	<0.001
Autoimmune disease	419,864 (7.3)	5,890 (16.2)	2.42 (2.35, 2.48)	<0.001
Cancer	309,673 (5.4)	4,644 (12.8)	2.55 (2.47, 2.63)	<0.001
Cardiovascular disease	596,768 (10.3)	14,237 (39.2)	5.49 (5.37, 5.60)	<0.001
Cerebrovascular	268,878 (4.7)	6,328 (17.4)	4.27 (4.16, 4.39)	<0.001
Chronic kidney disease	433,796 (7.5)	11,615 (32.0)	5.66 (5.53, 5.78)	<0.001
Chronic lung disease	432,819 (7.5)	9,253 (25.5)	4.18 (4.08, 4.28)	<0.001
Diabetes	833,567 (14.5)	16,993 (46.8)	5.06 (4.95, 5.16)	<0.001
Hemoglobin disorder	8,477 (0.2)	120 (0.3)	2.22 (1.85, 2.65)	<0.001
HIV/AIDS	11,862 (0.2)	161 (0.4)	2.19 (1.87, 2.55)	<0.001
Hypertension	1,988,065 (34.5)	28,856 (79.5)	7.04 (6.87, 7.22)	<0.001
Liver disease	10,861 (0.2)	271 (0.8)	4.30 (3.81, 4.84)	<0.001
Neurologic disease	224,551 (3.9)	7,622 (21.0)	6.81 (6.64, 6.99)	<0.001
Obesity	620,546 (10.8)	8,334 (23.0)	2.42 (2.37, 2.48)	<0.001

Solid organ transplant	15,719 (0.3)	389 (1.1)	3.90 (3.53, 4.31)	<0.001
Pregnancy	61,956 (1.1)	353 (1.0)	0.90 (0.81, 1.00)	0.06
Systemic corticosteroids	634,020 (11.0)	8,730 (24.0)	2.41 (2.35, 2.46)	<0.001
DMARDs	51,817 (0.9)	893 (2.5)	2.63 (2.47, 2.82)	<0.001
TNF-alpha inhibitors	16,585 (0.3)	112 (0.3)	1.05 (0.87, 1.26)	0.64
IL-6 inhibitors	>749 (>0.01)	<11 (<0.03)	1.60 (0.80, 3.20)	0.18
Other biologics	13,658 (0.2)	91 (0.3)	1.02 (0.83, 1.26)	0.84
Other immunosuppressive drugs	20,532 (0.4)	248 (0.7)	1.84 (1.62, 2.08)	<0.001

P-values calculated from Cox proportional hazards models. Reference groups for comorbidities and medications are the group of patients without the given disease or without a prescription for the given medication. SD=standard deviation; CI=confidence interval; HIV=human immunodeficiency virus; AIDS=acquired immunodeficiency syndrome; DMARDs=disease-modifying anti-rheumatic drugs; TNF-alpha=tumor necrosis factor alpha; IL-6=interleukin 6.